complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Published (Last):||24 February 2018|
|PDF File Size:||10.35 Mb|
|ePub File Size:||13.75 Mb|
|Price:||Free* [*Free Regsitration Required]|
Occurrence of secondary malignancy, usually acute myeloid leukemia with or without a preleukemic phase, has been reported following epirubicin. Epirubicinol mecajismo the one-tenth the cytotoxic activity of epirubicin and is not likely to contribute to the overall cytotoxic activity of epirubicin.
The esophagus can be especially sensitive. In the presence of doxorrbuicina, the semiquone radical can form a doxorrubicinq that in the presence of hydrogen peroxide forms a hydroxyl radical. Following skin or ocular exposure, skin and eyes should be thoroughly rinsed. The ECF regimen resulted in an increased response and survival benefit for patients with previously untreated gastric cancer or head and neck cancer.
It is prudent to closely monitor patients for loss of clinical efficacy of digoxin while receiving antineoplastic therapy. The immune response of the immunocompromised patient to vaccines is decreased and higher doses or more frequent boosters may be required. Women of childbearing potential should be warned against getting pregnant.
Treatment required colony stimulating factor support. Patients with a history of varicella doxorrubicinx, other herpes infections e. Those undergoing antineoplastic therapy should not be exposed to others who have recently received the oral poliovirus doxprrubicina OPV. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin.
This membrane protein functions as an energy-dependant drug efflux pump in resistant cells. Alopecia occurs in almost all patients receiving epirubicin therapy.
If extravasation occurs, stop the infusion and remove the tubing. These agents could enhance epirubicin’s activity. Those undergoing chemotherapy should not be exposed to others who have recently received the oral poliovirus vaccine OPV.
Several compounds including cyclosporine, cyclosporine analogs and verapamil may block this protein and reverse resistance. A second woman with breast cancer metastatic to the liver received fluorouracil, cyclophosphamide and epirubicin but was removed from the trial due to the pregnancy.
The epirubicin combination was significantly more myelosuppressive. It is not known if epirubicin is excreted in human breast milk but has been detected in breast milk of animals.
Doxorrubicina – Viquipèdia, l’enciclopèdia lliure
This reaction causes erythema, exfoliative dermatitis, pain, and burning, similar to that experienced with the original radiation therapy. Studies examining the use of the r-isomer of verapamil to block MDR, which has less cardiac effects, are underway. Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non-small cell lung cancer.
Dosage adjustments of antigout agents may be doxorrubbicina to control hyperuricemia.
Epirubicin has a similar spectrum of activity and toxicity as doxorubicin. Epirubicin is administered intravenously. Long-term survival after epirubicin, cisplatin, and fluorouracil for gastric cancer: Epirubicin and other anthracyclines induce cytotoxicity through several different mechanisms. Intramuscular injections should not be administered to patients with platelet counts 60 years. Nail discoloration, photosensitivity, and skin discoloration have been reported.
Symptoms of extravasation are usually immediate although extravasations into chest wall tissue are less acutely symptomatic. These changes do not necessitate dose modification or discontinuation and are not predictive of delayed cardiotoxicity. Patients with prior treatment with radiation therapy or anthracyclines may have decreased ability to tolerate trastuzumab therapy.
Epirubicin and its major metabolites are excreted through biliary excretion and to a lesser extent urinary excretion. At equimolar doses, epirubicin is less myelotoxic than doxorubicin.
Generally, this is not a problem in patients with breast cancer, but clinicians should closely monitor susceptible patients i. However, later events several months to years after ending treatment have been reported.
In one case, a woman was 28 weeks pregnant at her diagnosis of breast cancer and was treated with cyclophosphamide and epirubicin every 3 weeks for 3 cycles. Cimetidine therapy should be stopped during epirubicin therapy.
Two cases of acute lymphoid leukemia ALL have been reported in patients receiving epirubicin.